Skip to main content
Rayk Behrendt ERC grant
© David Fußhöller / UKB

News categories: Honors & Funding

Rayk Behrendt receives prestigious ERC Consolidator Grant

The ERC is funding the Professor for Nucleic Acid Immunity at the Bonn Cluster of Excellence with arround 2 million euros.

The human genome harbors large segments that offer no obvious benefit and can potentially even cause disease. Nevertheless, these areas are copied and maintained every time a cell divides, which means a considerable effort and energy cost for the body. What is the evolutionary advantage of preserving these areas? This is the question that virologist and immunologist Prof. Rayk Behrendt from the Cluster of Excellence ImmunoSensation2 at the University of Bonn is addressing. For his research, he now receives the prestigious Consolidator Grant of the European Research Council (ERC). The selected project of the Bonn professor will be funded with about 2 million euros.

The human genome is a constantly evolving database that can look back on a history spanning millions of years. Viruses able to integrate into the genome have left their traces in particular: Almost half of our genome is now occupied by ancient viral sequences. Under certain conditions, these sequences can be mobilized and jump from one location to another or copy themselves. However, the majority of these appear to be useless and even potentially dangerous to our health. "In recent years, it has been clearly shown that such so-called endogenous retroelements are associated with the development of inflammatory diseases and inflammation-induced aging, and can also cause cancer," says Prof. Rayk Behrendt of the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn. "We are therefore interested in understanding potential benefits of maintaining these elements in our genomes."

Do retroelements train our immune system?

Endogenous retroelements are only sporadically transcribed in healthy cells. However, they could play an important role in enabling the immune system by activating intracellular nucleic acid sensors that alert the cell to viral infections. "We are particularly intrigued by the question of how the transcription of retroelements is regulated in response to everyday stress situations such as viral infections or DNA damage," says Rayk Behrendt. In mice, it will be investigated how retroelements are sensed by the innate immune system and if this has functional consequences for establishing protective and pathologic immunity. The researchers also want to break new ground technically and develop a new so-called deep-sequencing workflow that will allow them to determine the exact genomic origin of each retroelement.

Promising young researchers for the University of Bonn

Rayk Behrendt completed his PhD at the Robert Koch Institute and the Humboldt University of Berlin. He then conducted research at the Institute of Immunology at the Technical University of Dresden, where he led the research group "Cell-intrinsic Immunity and Genome Defense" from 2017. Since March of this year, Behrendt is Professor for Nucleic Acid Immunity at the University of Bonn and the University Hospital Bonn. The now acquired ERC Consolidator Grant is awarded to first-class young scientists to support them in consolidating their scientific independence. "I have been intrigued by the underlying question of the project for quite a long time. I am super grateful for this award, which gives me the opportunity to really push our boundaries in this field,” says Behrendt. “I am happy that it happens right now, after I joined the exceptional scientific community at the Institute of Clinical Chemistry and Clinical Pharmacology and the Cluster of Excellence ImmunoSensation2 at the University of Bonn.” Rayk Behrendt is also a member of the Transdisciplinary Research Area "Life and Health"


Contact

Prof. Dr. Rayk Behrendt

Institute for Clinical Chemistry and Clinical Pharmacology

University Hospital Bonn

Phone: +49 228 287 51120

E-mail: behrendt@uni-bonn.de

Related news

Gut

News categories: Honors & Funding

Millions in funding for the new MikrobiomProCheck research project

The human gut microbiome is as unique as a fingerprint. It plays a central role in chronic inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Yet its potential for diagnostics and personalized therapy for patients remains untapped. The MikrobiomProCheck research project aims to change this. To this end, the Leibniz Institute for Analytical Sciences (ISAS), the Universities of Bonn, Bielefeld, and Duisburg-Essen, Biofidus AG, and Lead Discovery Center GmbH are receiving approximately 3.4 million euros from the state government of NRW and the European Union.
View entry
Zwei Personen: Links Prof. Pröpstl und rechts Prof. Boztug

News categories: Honors & Funding

University of Bonn and University Hospital Bonn strengthen early-career clinical scientists

The Faculty of Medicine at the University of Bonn and the University Hospital Bonn (UKB) are jointly launching the EKFS doctoral program IMMUNE PILOT, which introduces medical students to clinical-scientific research at an early stage. The structured program is positioned at the interface of immunology, neuroscience, and genetics and is aimed at students with a strong interest in research who aspire to pursue a career as clinician scientists. The program is funded by the Else Kröner-Fresenius Foundation (EKFS).
View entry
PrepAIred

News categories: Honors & Funding

Precise active ingredients against pancreatic cancer

Pancreatic cancer remains one of the deadliest forms of cancer. At the German Cancer Congress 2026, German Cancer Aid is now presenting three large-scale projects that it is funding as part of its “German Alliance for Pancreatic Cancer” funding priority. In the funded project PrepAIred, Bonn researchers , in cooperation with the University of North Carolina (USA), want to use AI-based protein design to specifically combat pancreatic cancer. German Cancer Aid is funding the project with a total of 1.99 million euros over a period of four years.
View entry

Back to the news overview